Latest Market Entry News

Bioxyne expands its LATAM footprint by securing the first international medicinal cannabis flower supply agreement in Costa Rica, with initial shipments valued over $500,000 planned before June 2026.

BCAL Diagnostics appoints Anne-Louise Arnett as CEO effective June 2026, aiming to accelerate its commercial rollout and international market entry of early cancer detection tests.

Pure Resources has launched an integrated Defence Materials Platform Strategy for its Garnet Hills Project, leveraging US government collaborations to diversify from commodity mining into advanced defence supply chains.

Me Today has raised its full-year revenue forecast to over NZD 7.4 million, driven by strong domestic sales and a new exclusive distribution deal in Southeast Asia. The nutritional supplements company also expects a 25% reduction in EBITDA loss, reflecting tighter cost control amid ongoing product innovation.

Volt Resources is making headway in securing US customers for its Alabama Graphite Refinery, leveraging recent policy shifts and supply chain dynamics to target near-term revenue from industrial and battery markets.

Sigma Healthcare reports robust growth in Chemist Warehouse sales across Australia and internationally, announces a joint venture to enter the UK market, and secures a major distribution centre lease in New Zealand to support its expanding network.

Merino & Co. has secured a three-year exclusive distribution agreement in Mainland China, guaranteeing a minimum annual order of CNY 30 million (~AUD 6.5 million) and targeting 20% yearly growth upon renewal.

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.

Environmental Clean Technologies (ASX: ECT) has advanced its PFAS remediation technology with a scalable high-voltage system achieving 1,000°C without additives, expanded its Flash Joule Heating licence to water treatment adsorbents, and formed an expert Advisory Board to accelerate commercialisation.

Alterity Therapeutics secures FDA backing on key Phase 3 elements for ATH434 in Multiple System Atrophy, bolstered by fresh Phase 2 data showing slowed disease progression and strategic leadership hires.

ReNerve Limited reports a 79% jump in quarterly sales, secures key Asia-Pacific approvals, and progresses its nerve repair pipeline with the NervAlign Nerve Guide Matrix entering Stage 3 development.

TrivarX has made significant strides in preparing its Stabl-Im stable isotope imaging platform for Phase 1 clinical trials, backed by strengthened leadership and a solid cash reserve of $2.91 million.